lung disease

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Biotech By Adam Feuerstein

Stoke Therapeutics drug, targeting genetic cause of childhood epilepsy, reduces seizure activity

Pharmalot By Ed Silverman

Pharmalittle: FDA plans rapid review of Omicron vaccines and drugs; Califf would keep Woodcock at FDA

First Opinion By Ian Tong

In defense of not treating everyone the same

First Opinion By Kushal Kadakia and Harlan M. Krumholz

Reforms needed for FDA’s regulation of medical devices

In the Lab By Andrew Joseph

We’ll know more soon about Omicron. Here’s how to interpret the coming flood of data

Health By Megan Molteni

‘Just stupid stuff’: Logistics and lack of testing stymied finding the Omicron variant in the U.S.

Pharmalot By Ed Silverman

Former Immunomedics executives are charged with insider trading